

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

ELAN CORP PLC  
Form SC 13D/A  
November 05, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

SCHEDULE 13D/A1 (Amendment No. 1)\*  
Under the Securities Exchange Act of 1934

Targeted Genetics Corporation

---

(Name of Issuer)

Common Stock, par value \$.01 per share

---

(Title of Class of Securities)

87612M108

---

(CUSIP Number)

William F. Daniel  
Elan Corporation, plc  
Lincoln House  
Lincoln Plaza  
Dublin 2, Ireland  
(353) 1-709-4000

---

(Name, Address and Telephone Number of Person Authorized  
to Receive Notices and Communications)

Earliest event August 9, 2000

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ].

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

-----  
CUSIP No. 249908-10-4  
-----

(1) NAME OF REPORTING PERSONS  
-----

Elan Corporation, plc  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)  
N/A  
-----

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See  
Instructions)

(a)

(b)

-----  
(3) SEC USE ONLY  
-----

(4) SOURCE OF FUNDS (See Instructions)  
WC, 00  
-----

(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT  
TO ITEMS 2(d) or 2(e)

(6) CITIZENSHIP OR PLACE OF ORGANIZATION  
Ireland  
-----

Number of (7) SOLE VOTING POWER  
Shares 0  
-----

Beneficially (8) SHARED VOTING POWER  
Owned 12,599,073  
-----

by Each (9) SOLE DISPOSITIVE POWER  
Reporting 0  
-----

Person With (10) SHARED DISPOSITIVE POWER  
12,599,073  
-----

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
12,599,073  
-----

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN  
SHARES (See Instructions)

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
17.7%  
-----

(14) TYPE OF REPORTING PERSON (See Instructions) CO  
-----

-----  
CUSIP No. 249908-10-4  
-----

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

-----

(1) NAME OF REPORTING PERSONS Elan International Services, Ltd.  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)  
N/A

-----

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See  
Instructions) (a) [ ]  
(b) [ ]

-----

(3) SEC USE ONLY

-----

(4) SOURCE OF FUNDS (See Instructions)  
WC, OO

-----

(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT  
TO ITEMS 2(d) or 2(e) [ ]

-----

(6) CITIZENSHIP OR PLACE OF ORGANIZATION  
Bermuda

-----

Number of Shares	(7)	SOLE VOTING POWER 0
Beneficially Owned	(8)	SHARED VOTING POWER 12,599,073
by Each Reporting	(9)	SOLE DISPOSITIVE POWER 0
Person With	(10)	SHARED DISPOSITIVE POWER 12,599,073

-----

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
12,599,073

-----

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN  
SHARES (See Instructions) [ ]

-----

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
17.7%

-----

(14) TYPE OF REPORTING PERSON (See Instructions) CO

Page 3 of 12

Item 1. Security and Issuer.

Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

This Amendment No. 1 amends the Schedule 13D filed with the Securities and Exchange Commission on August 9, 1999 by Elan International Services, Ltd. ("EIS"), a Bermuda exempted limited liability company and wholly-owned subsidiary of Elan Corporation, plc ("Elan"), an Irish public limited company

## Edgar Filing: ELAN CORP PLC - Form SC 13D/A

(the "Schedule 13D"), with respect to the Common Stock, par value \$.01 per share (the "Common Stock"), of Targeted Genetics Corporation (the "Issuer"), a Washington corporation whose principal offices are located at 1100 Olive Way, Suite 100, Seattle, Washington 98101.

### Item 2. Identity and Background.

Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:

This Schedule 13D is filed by Elan and EIS. Elan's principal place of business is Lincoln House, Lincoln Place Dublin 2, Ireland. Elan is a worldwide pharmaceutical company. EIS's principal place of business is 102 St. James Court, Flatts, Smiths, FL 04 Bermuda. EIS is an investment and holding company.

Schedule A to this Schedule 13D sets forth the (a) name, (b) residence or business address, (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and (d) citizenship or place of organization of each executive officer, director and controlling person of Elan and EIS.

During the last five years, neither Elan, EIS nor any person identified on Schedule A to this Schedule 13D: (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which proceeding it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, United States federal or state securities laws, or finding any violation with respect to such laws.

### Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

Pursuant to a Securities Purchase Agreement dated July 21, 1999 by and among Elan and EIS, on the one hand, and the Issuer, on the other hand (the "Securities Purchase Agreement"), EIS acquired (a) 2,148,899 shares of Common Stock of the Issuer for consideration of \$5,000,000 and (b) 12,015 shares of Series B Convertible Exchangeable Preferred Stock, \$0.01 par value per share (the "Series B Preferred Stock"), of the Issuer for consideration of \$12,015,000. The source of the funds used in acquiring the above-referenced securities was working capital.

The Series B Preferred Stock accrues dividends until July 21, 2005 at an annual rate of 7.0% of \$1,000 per share plus accrued dividends thereon, compounded semi-annually, payable by the issuance of additional shares of Common Stock upon conversion of the Series B Preferred Stock. Each share of Series B Preferred Stock is convertible, without payment of any additional consideration by the holder and at the option of the holder, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing \$1,000 plus any accrued and unpaid dividends by a conversion price of \$3.32 per share of Common Stock, subject to customary antidilution adjustments; provided, that, to the extent such conversion would result in EIS holding more than 19.99% of the Issuer's Common Stock, Series B Preferred Stock may be converted into non-voting stock at the option of the holder or in certain circumstances redeemed for cash at the option of the Issuer. As of November 5, 2003, the Series B Preferred Stock plus accrued dividends would be convertible into an

## Edgar Filing: ELAN CORP PLC - Form SC 13D/A

aggregate of 4,864,191 shares of Common Stock. If the Series B Preferred Stock is held by the holder until at least July 21, 2005, the date on which dividends cease to accrue, the Series B Preferred Stock and accrued dividends will be convertible into an aggregate of 5,470,546 shares.

Upon the exercise by the Issuer of a right to require EIS to purchase additional shares of Common Stock pursuant to the Securities Purchase Agreement, on August 9, 2000, EIS acquired 382,739 shares of Common Stock of the Issuer for consideration of \$5,000,000. The source of the funds used in acquiring these shares of Common Stock of the Issuer was working capital.

In addition, pursuant to the Securities Purchase Agreement, the Issuer issued to EIS a convertible promissory note in an aggregate principal amount of up to \$12,015,000 (the "Convertible Note"). The Convertible Note was subsequently transferred to Elan Pharma International Limited, an affiliate of EIS and wholly-owned subsidiary of Elan, but the right to convert the Convertible Note and receive Common Stock upon conversion was retained by EIS. The Issuer made draw-downs in the aggregate amount of \$7,950,000, on the following dates and in the following amounts: September 26, 2001 (\$2,000,000), April 25, 2002 (\$2,000,000), June 28, 2002 (\$3,000,000), and August 9, 2002 (\$950,000). Interest on each drawdown of the Convertible Note accrued at an annual rate of 12.0%, compounded on each semi-annual anniversary of such drawdown. At the Issuer's option, accrued interest was capitalized and added to the principal amount outstanding on each compounding date. The Convertible Note had a stated maturity of July 21, 2005. Each tranche (consisting of a drawdown or accrual of interest) of the Convertible Note was convertible at any time prior to repayment in full into a number of shares of Common Stock equal to the principal amount of such tranche and all accrued and unpaid interest thereon divided by a per share price calculated as 150% of the average of the closing price of the Common Stock for the 60 trading days ending two business days prior to the date that the tranche was requested by the Issuer. As of September 2, 2003, the date of repayment of the Convertible Note, the Convertible Note was convertible at the option of the holder into 5,203,243 shares of Common Stock. In addition, the Convertible Note was prepayable at the option of the Issuer on a per tranche basis by the issuance of a number of shares of Common Stock equal to the outstanding principal amount of such tranche and any and all accrued and unpaid interest thereon divided by the lesser of (1) the price equal to the average of the closing price of the Common Stock for the 60 trading days prior to the date of repayment and (2) the conversion price for conversion at the option of the holder of the conversion right.

#### Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows:

EIS acquired the above-referenced securities for investment purposes or as interest on the Convertible Promissory Note.

The Issuer has granted to EIS certain demand and piggyback registration rights for the shares of Common Stock held by EIS and for the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.

EIS and the Issuer have agreed in the Securities Purchase Agreement that for so long as EIS and/or its affiliates or subsidiaries collectively own at least 5% of the shares of Common Stock and/or common stock equivalents of the Issuer on a fully diluted basis, EIS will have the right to nominate one director for election to the Issuer's Board of Directors who shall be a member of senior management of Elan, or otherwise shall be acceptable to the Issuer; provided, however, that the Issuer reserves the right to exclude such director from any material or meeting or portion thereof if the other Board members believe in good faith that such exclusion is reasonably necessary to protect

## Edgar Filing: ELAN CORP PLC - Form SC 13D/A

confidential proprietary information, for competitive or similar reasons. EIS has not to date nominated a director.

Except as set forth above in Item 3 or this Item 4 above, neither Elan nor EIS has any plan or proposal which relates to or would result in:

Page 5 of 12

(a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

(b) An extraordinary corporate transaction such as a merger, reorganization or liquidation involving the Issuer or any of its subsidiaries;

(c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d) Any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number of term of Directors or to fill any existing vacancies on the Board;

(e) Any material change in the present capitalization or dividend policy of the Issuer;

(f) Any other material change in the Issuer's business or corporate structure;

(g) Changes in the Issuer's charter, by-laws, or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(h) Causing the Common Stock to cease to be authorized to be traded on the Nasdaq National Market;

(i) To have the Common Stock terminated from registration under the Securities Act of 1933; or

(j) Any action similar to any of those enumerated above.

### Item 5. Interest in Securities of Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) As of November 5, 2003, Elan (indirectly) and EIS (directly) each beneficially owned 12,599,073 shares of Common Stock (including 7,734,882 shares of Common Stock and 4,864,191 shares issuable upon conversion of the Series B Preferred Stock), representing 17.7% of the outstanding shares of Common Stock (based on 71,064,821 shares of Common Stock outstanding, including 66,200,630 shares of Common Stock outstanding on October 26, 2003, as reported in the Issuer's quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2003 and 4,864,191 shares issuable upon conversion of the Series B Preferred Stock).

(b) As of November 5, 2003, Elan and EIS have shared voting and dispositive power over 12,599,073 shares of Common Stock (including 4,864,191 shares of Common Stock issuable upon conversion of the Series B Preferred Stock) and no sole voting or dispositive power over shares of Common Stock.

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

(c) On September 2, 2003, EIS acquired an aggregate of 5,203,243 shares of the Common Stock as repayment of all principal of and accrued interest on the Convertible Note at the following prices: (a) 3,577,879 shares at a price of \$2.09, (b) 487,248 shares at a price of \$1.95, (c) 101,439 shares at a price of \$1.88, (d) 107,044 shares at a price of \$1.19, (e) 124,630 shares at a price of \$0.96, (f) 217,549 at a price of \$0.83, (g) 87,922 at a price of \$0.65, (h) 221,757 at a price of \$0.57 and (i) 277,775 at a price of \$0.49.

(d) Not applicable.

Page 6 of 12

(e) Not applicable.

Item 6. Contracts, Arrangements, Understanding or Relationships with Respect to Securities of the Issuer.

Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The Securities Purchase Agreement provided that, except with respect to certain permitted transfers or assignments, EIS is restricted from transferring or assigning the Series B Preferred Stock, the Common Stock, or the Convertible Note, or any interest therein, without the prior written consent of the Issuer.

Except as described in Items 3 and 4, there are no other contracts, arrangements, understandings or relationships described in Item 6 of Schedule 13D.

Item 7. Material to Be Filed as Exhibits.

Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows:

1. Joint Filing Agreement dated November 5, 2003 between Elan and EIS.\*
2. Securities Purchase Agreement, dated as of July 21, 1999.\*\*
3. Convertible Promissory Note, dated July 21, 1999.\*\*
4. Articles of Amendment of the Issuer incorporating the Designation of Rights and Preferences of Series B Preferred Stock filed with the State of Washington on July 21, 1999.\*\*
5. Registration Rights Agreement, dated as of July 21, 1999.\*\*

---

\* Filed herewith.

\*\* Incorporated by reference to the Issuer's Current Report on Form 8-K dated August 4, 1999 (Commission File No. 000-23930).

Page 7 of 12

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: November 5, 2003

ELAN CORPORATION, PLC

By: /s/ Shane M. Cooke

-----  
Name: Shane M. Cooke  
Title: Chief Financial Officer

Dated: November 5, 2003

ELAN INTERNATIONAL SERVICES, LTD.

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: Chief Financial Officer

Page 8 of 12

SCHEDULE A

The (a) name, (b) state or other place of its organization, (c) principal business, (d) address of its principal business and (e) address of its principal office of Elan is set forth below:

(a) Elan Corporation, plc, (b) Ireland, (c) a worldwide biopharmaceutical company, (d) Lincoln House, Lincoln Place, Dublin 2, Ireland, and (e) Lincoln House, Lincoln Place, Dublin 2, Ireland.

The (a) name, (b) business address, (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and (d) citizenship of each executive officer and director (other than Messrs. Armen, Boushel, Crowley, Gillespie, Groom, McGowan, McIntyre, McLaughlin, Selkoe, Thornburgh and Tully and Ms. Gray) of Elan are set forth below:

1. (a) G. Kelly Martin, (b) 345 Park Avenue, New York, New York 10154, (c) President and Chief Executive Officer, and (d) United States.
2. (a) Shane Cooke, (b) Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Executive Vice President and Chief Financial Officer, and (d) Ireland.
3. (a) William F. Daniel (b) Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Executive Vice President and Company Secretary, and (d) Ireland.
4. (a) Jean Duvall, (b) 800 Gateway Blvd., South San Francisco, CA 94080, (c) Executive Vice President and General Counsel, and (d) United States.

The (a) name, (b) business address, (c) present principal occupation or



## Edgar Filing: ELAN CORP PLC - Form SC 13D/A

employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and (d) citizenship of each director (other than Messrs. Martin and Daniel) of Elan are set forth below:

1. (a) Garo A. Armen, Ph.D., (b) 630 Fifth Avenue, Suite 2167, New York, New York 10111, (c) Chairman of the Board and Chief Executive Officer of Antigenics, Inc., and (d) United States.
2. (a) Brendan E. Boushel, (b) 9 Upper Mount Street, Dublin 2, Ireland, (c) Retired, and (d) Ireland.
3. (a) Laurence G. Crowley, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Governor (Chairman) Bank of Ireland, and (d) Ireland.
4. (a) Alan R. Gillespie, Ph.D., (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Chairman, Ulster Bank Limited, and (d) United Kingdom.
5. (a) Ann Maynard Gray, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Retired, and (d) United Kingdom.
6. (a) John Groom, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Retired, and (d) United Kingdom.
7. (a) Kieran McGowan, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place Dublin 2, Ireland, (c) Retired, and (d) Ireland.
8. (a) Kevin McIntyre, M.D., (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Associate Clinical Professor of Medicine at Harvard Medical School, and (d) United States.

Page 9 of 12

9. (a) Kyran McLaughlin, (b) Davy House, 49 Dawson Street, Dublin 2, Ireland, (c) Head of Equities and Corporate Finance, Davy Stockbrokers, and (d) Ireland.
10. (a) Dennis J. Selkoe, M.D., (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Professor of Neurology and Neuroscience at Harvard Medical School, and (d) United States.
11. (a) Richard L. Thornburgh, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Counsel to the law firm of Kirkpatrick & Lockhart LLP, and (d) United States.
12. (a) Daniel P. Tully, (b) c/o Elan Corporation, plc, Lincoln House, Lincoln Place, Dublin 2, Ireland, (c) Retired, and (d) United States.

The (a) name, (b) business address, (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and (d) citizenship of each executive officer and director of EIS are set forth below:

1. Kevin Insley, (b) c/o 102 St. James Court, Flatts, Smiths Bermuda, (c) Director, President and Chief Financial Officer, and (d) United Kingdom.
2. (a) Debra Moore Buryj, (b) c/o 102 St. James Court, Flatts, Smiths, Bermuda, (c) Director and Vice President and, (d) United States.

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

3. (a) David J. Doyle, (b) c/o Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda, (c) Director of EIS, and principal occupation is lawyer, law firm of Conyers, Dill & Pearman, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda, and (d) Bermuda.

Page 10 of 12

EXHIBIT INDEX

1. Joint Filing Agreement dated November 5, 2003 between Elan and EIS.\*
2. Securities Purchase Agreement, dated as of July 21, 1999.\*\*
3. Convertible Promissory Note, dated July 21, 1999.\*\*
4. Articles of Amendment of the Issuer incorporating the Designation of Rights and Preferences of Series B Preferred Stock filed with the State of Washington on July, 21, 1999.\*\*
5. Registration Rights Agreement, dated as of July 21, 1999.\*\*

---

\* Filed herewith.

\*\* Incorporated by reference to the Issuer's Current Report on Form 8-K dated August 4, 1999 (Commission File No. 000-23930).

Page 11 of 12

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Amendment No. 1 to Schedule 13D with respect to the Common Stock of Targeted Genetics Corporation, dated as of November 5, 2003 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

Dated: November 5, 2003

ELAN CORPORATION, PLC

By: /s/ Shane M. Cooke

-----  
Name: Shane M. Cooke  
Title: Chief Financial Officer

Dated: November 5, 2003

ELAN INTERNATIONAL SERVICES, LTD.

Edgar Filing: ELAN CORP PLC - Form SC 13D/A

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: Chief Financial Officer

Page 12 of 12